TECHNE CORPORATION DECLARES DIVIDEND AND ANNOUNCES AN INCREASE
                     IN ITS SHARE REPURCHASE PROGRAM


Minneapolis/April 28, 2009/--Techne Corporation (NASDAQ:TECH) announced that
its Board of Directors has decided to pay a dividend of $0.25 per share for
the quarter ended March 31, 2009.  The quarterly dividend will be payable May
22, 2009 to all common shareholders of record on May 8, 2009.  Future cash
dividends will be considered by the Board of Directors on a quarterly basis.

Techne's Board of Directors also authorized the repurchase of an additional
$60 million of the Company's common stock in connection with its ongoing
share repurchase program, which does not have an expiration date. Including
the above amount, the total share repurchase authorization remaining is
approximately $67.5 million. Repurchases under the program will be at the
discretion of management and may be made in open market, pursuant to one or
more 10b5-1 plans, structured transactions, privately negotiated transactions
or otherwise, from time to time, depending on market conditions.  The stock
repurchase program may be modified or discontinued at any time.  The share
repurchase will be funded with a portion of the Company's existing cash and
available-for-sale investments.

                  *  *  *  *  *  *  *  *  *  *  *  *  *  *

Techne Corporation has two operating subsidiaries:  Research and Diagnostic
Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe,
Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty
manufacturer of biological products.  R&D Systems has two subsidiaries,
BiosPacific, Inc. (BiosPacific), located in Emeryville, California and R&D
Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacific
is a worldwide supplier of biologics to manufacturers of in vitro diagnostic
systems and immunodiagnostic kits. R&D China and R&D Europe distribute
biotechnology products.


Contact:  Greg Melsen, Chief Financial Officer
          Kathy Backes, Controller
          (612) 379-8854